SPP1 and pancreatic ductal adenocarcinoma: In line with this observation, using OPN dosage in serum as a non-invasive biomarker is supported by extensive evidence generated in pancreatic ductal adenocarcinoma and ovarian carcinoma, showing its suitability to evaluate tumor progression and to predict post-operative complications, as found in colorectal cancer [36,37].